Form 4: Director Sells STOK Shares Under 10b5-1 Plan

Stoke Therapeutics Director Adrian R. Krainer sold 7,229 shares of common stock for approximately $286,700 under a pre-arranged trading plan.

Summary

• Adrian R. Krainer, a Director of Stoke Therapeutics, Inc. (STOK), disposed of 7,229 shares of common stock.
• The transaction occurred on March 2, 2026.
• The shares were sold at a weighted average price of $39.6618 per share, with prices ranging from $39.50 to $39.80.
• The total value of the shares sold is approximately $286,700 (7,229 shares * $39.6618/share).
• Following this transaction, Krainer directly beneficially owns 316,545 shares of Stoke Therapeutics common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Krainer on August 15, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine insider transaction under a pre-arranged 10b5-1 plan, which typically mitigates negative sentiment associated with insider selling.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence or a signal that the stock may be fully valued.
• The sale reduces the director's direct ownership stake in the company.

Risks

• Market perception risk: Insider sales, even pre-planned, can sometimes lead to negative market sentiment or speculation about the company's future prospects.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider sales, particularly by directors, are common in the biotechnology sector, often occurring under pre-arranged 10b5-1 plans for personal financial planning. While this specific transaction is small relative to the company's market capitalization, it is part of the ongoing disclosure requirements for executives and directors in the industry.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice for executives and directors across all industries, including biotechnology, to manage personal finances while complying with insider trading regulations. There are no specific comparable companies or projects mentioned in this Form 4 to assess against.

Stakeholder Impact

• Shareholders: May interpret the sale as a minor negative signal, though the 10b5-1 plan context often softens this.

Key Dates

Recommendation

The transaction is a routine insider sale under a pre-arranged 10b5-1 plan, which does not provide new fundamental information about Stoke Therapeutics. While insider selling can sometimes be a bearish signal, the pre-planned nature suggests personal financial management rather smarter than a reaction to adverse company developments. Therefore, a 'hold' recommendation is appropriate as this filing alone does not warrant a change in investment thesis.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Adrian R. Krainer, Director, Stock Sale, 10b5-1 Plan, Biotechnology, SEC Filing